JP2022532998A5 - - Google Patents

Info

Publication number
JP2022532998A5
JP2022532998A5 JP2021563623A JP2021563623A JP2022532998A5 JP 2022532998 A5 JP2022532998 A5 JP 2022532998A5 JP 2021563623 A JP2021563623 A JP 2021563623A JP 2021563623 A JP2021563623 A JP 2021563623A JP 2022532998 A5 JP2022532998 A5 JP 2022532998A5
Authority
JP
Japan
Prior art keywords
premrna
target protein
aic
protein
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021563623A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022532998A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/029953 external-priority patent/WO2020219977A1/en
Publication of JP2022532998A publication Critical patent/JP2022532998A/ja
Publication of JP2022532998A5 publication Critical patent/JP2022532998A5/ja
Priority to JP2025087686A priority Critical patent/JP2025128180A/ja
Pending legal-status Critical Current

Links

JP2021563623A 2019-04-26 2020-04-24 選択的イントロンのスプライシングを調節するための方法及び組成物 Pending JP2022532998A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025087686A JP2025128180A (ja) 2019-04-26 2025-05-27 選択的イントロンのスプライシングを調節するための方法及び組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962839572P 2019-04-26 2019-04-26
US62/839,572 2019-04-26
PCT/US2020/029953 WO2020219977A1 (en) 2019-04-26 2020-04-24 Methods and compositions for modulating splicing of alternative introns

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025087686A Division JP2025128180A (ja) 2019-04-26 2025-05-27 選択的イントロンのスプライシングを調節するための方法及び組成物

Publications (2)

Publication Number Publication Date
JP2022532998A JP2022532998A (ja) 2022-07-21
JP2022532998A5 true JP2022532998A5 (cg-RX-API-DMAC10.html) 2023-04-28

Family

ID=72941393

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021563623A Pending JP2022532998A (ja) 2019-04-26 2020-04-24 選択的イントロンのスプライシングを調節するための方法及び組成物
JP2025087686A Pending JP2025128180A (ja) 2019-04-26 2025-05-27 選択的イントロンのスプライシングを調節するための方法及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025087686A Pending JP2025128180A (ja) 2019-04-26 2025-05-27 選択的イントロンのスプライシングを調節するための方法及び組成物

Country Status (10)

Country Link
US (1) US20220162599A1 (cg-RX-API-DMAC10.html)
EP (1) EP3959313A4 (cg-RX-API-DMAC10.html)
JP (2) JP2022532998A (cg-RX-API-DMAC10.html)
KR (1) KR20220019676A (cg-RX-API-DMAC10.html)
CN (1) CN114127286A (cg-RX-API-DMAC10.html)
AU (1) AU2020263581A1 (cg-RX-API-DMAC10.html)
BR (1) BR112021021384A2 (cg-RX-API-DMAC10.html)
CA (1) CA3134947A1 (cg-RX-API-DMAC10.html)
MX (1) MX2021013081A (cg-RX-API-DMAC10.html)
WO (1) WO2020219977A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023348346A1 (en) * 2022-09-30 2025-03-27 Contera Pharma A/S Antisense oligonucleotides for the treatment of canavan disease
CN121059628A (zh) * 2024-06-03 2025-12-05 时夕(广州)生物科技有限公司 调控RNA剪接的向导agRNA

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005535318A (ja) * 2002-08-12 2005-11-24 ユニヴェルシテ ドゥ シェルブルック プレメッセンジャーrnaのスプライス部位選択の再プログラミング方法
EP3578657B1 (en) * 2010-04-06 2024-03-20 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of cd274/pd-l1 gene
WO2015108907A2 (en) * 2014-01-14 2015-07-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
CN107109411B (zh) * 2014-10-03 2022-07-01 冷泉港实验室 核基因输出的定向增加
WO2017100587A1 (en) * 2015-12-09 2017-06-15 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting programmed cell death 1 ligand 1 (pd-l1) and methods of use thereof
CN116059236A (zh) * 2015-12-14 2023-05-05 冷泉港实验室 用于治疗常染色体显性精神发育迟滞5型和Dravet综合征的反义寡聚体
CA3013683C (en) * 2016-03-14 2021-07-13 F. Hoffmann-La Roche Ag Oligonucleotides for reduction of pd-l1 expression
SG10201705285SA (en) * 2017-06-27 2019-01-30 Agency Science Tech & Res Antisense oligonucleotides

Similar Documents

Publication Publication Date Title
JP2022500066A5 (cg-RX-API-DMAC10.html)
JP2023145597A (ja) Rnaを編集するための組成物および方法
JP2024056778A5 (cg-RX-API-DMAC10.html)
KR102939954B1 (ko) 다논병 및 다른 자가포식 장애의 치료 방법
JP2017519766A5 (cg-RX-API-DMAC10.html)
EP4344741A2 (en) Aav vectors targeted to the central nervous system
EP2146736B1 (en) Srpin340 as modulator of vegf splicing and anti-angiogenic agents
US20220127612A1 (en) Methods and compositions for modulating splicing and translation
JP2021500041A5 (cg-RX-API-DMAC10.html)
JP2021522842A5 (cg-RX-API-DMAC10.html)
JP2019501892A5 (cg-RX-API-DMAC10.html)
JP2022544702A5 (cg-RX-API-DMAC10.html)
CN108368508A (zh) 用于抗肌萎缩蛋白外显子53跳读的有效基因治疗工具
JP2019500347A5 (cg-RX-API-DMAC10.html)
JP7756166B2 (ja) Rna治療薬及びその使用方法
RU2018145010A (ru) Оптимизированные гены и экспрессионные кассеты cln1, и их применение
JP7048574B2 (ja) アンチセンスオリゴヌクレオチドおよび糖原病Ia型予防または治療用組成物
JP2022513454A (ja) AIMP2-DX2およびmiR-142の標的核酸を含むベクター、ならびにその使用
WO2021247995A2 (en) Compositions and methods of treating neuropathic pain
JP2022522205A5 (cg-RX-API-DMAC10.html)
JP2023500793A5 (cg-RX-API-DMAC10.html)
CN114269925A (zh) Apoe4 rna特异性反式剪接核酶及其用途
CN119403926A (zh) 用于减少富亮氨酸重复激酶2(lrrk2)的表达的寡核苷酸及其用于预防和/或治疗人类疾病的用途
CN119497756A (zh) 方法
US20220162599A1 (en) Methods and compositions for modulating splicing of alternative introns